Top Anti-snoring Devices And Snoring Surgery Companies

Global Anti-snoring Devices and Snoring Surgery Market size was valued at USD 1.63 Billion in 2024 and is poised to grow from USD 1.76 Billion in 2025 to USD 3.13 Billion by 2033, growing at a CAGR of 7.5% during the forecast period (2026–2033). 

Global Anti-snoring Devices and Snoring Surgery Market is highly fragmented with several global as well as local players. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies such as innovations, mergers, and acquisitions, collaborations and partnerships. Key players in the market include Sleeping Well, LLC, Apnea Sciences Corporation, Tomed Dr. Toussaint GmbH, Sleep Well Enjoy Life, Ltd., and MEDiTAS Ltd. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. 'ResMed Inc. (USA) ', 'Koninklijke Philips N.V. (Netherlands) ', 'Fisher & Paykel Healthcare Corporation Limited (New Zealand) ', 'SomnoMed Limited (Australia) ', 'Tomed Dr. Toussaint GmbH (Germany) ', 'Meditas Ltd. (UK) ', 'GlaxoSmithKline plc (UK) ', 'Olympus Corporation (Japan) ', 'Endo Pharmaceuticals Inc. (USA) ', 'KARL STORZ SE & Co. KG (Germany) ', 'Natus Medical Incorporated (USA) ', 'MPowrx Health and Wellness Products (Canada) ', 'PureSleep Company (USA) '

Growing alcohol and cigarette use, as well as technical advancements in the design of anti-snoring devices, are also projected to support market expansion.

For obstructive sleep apnea (OSA), continuous positive airway pressure (CPAP) is the recommended first-line treatment. For the majority of OSA sufferers, it is quite effective at reducing OSA severity. Aside with these potential advantages, CPAP may also lower blood pressure and enhance daytime drowsiness and cognitive performance. However, poor CPAP therapy adherence frequently limits these health advantages. For mild-to-moderate OSA and as a backup treatment for CPAP intolerance, oral appliance therapy is advised. For patients who don't react fully to oral appliance therapy, combination therapy with CPAP and an oral appliance (CPAP + OA) may be an option. In comparison to CPAP alone, combined therapy employing CPAP and oral appliance therapy can stabilise pharyngeal pressure fluctuations and reduce CPAP requirements by 35 to 45 percent. Patients with OSA who don't react well to oral appliance therapy alone or who have trouble using CPAP owing to the high pressure needs may benefit from combination therapy.

North America region held the highest share in the Global Anti-snoring Devices and Snoring Surgery Market and amounted for the largest share of revenue in 2021.This is explained by the high prevalence of snoring in the United States. For instance, a 2022 report from John Hopkins University claimed that 25% of individuals snore often and that 45 percent of adults snore sometimes. According to a different study by the Sleep Foundation, snoring affects an estimated 57 percent of males and 40 percent of women in the United States. Even youngsters, who make up an estimated 27% of the population, are reportedly afflicted. Growing obesity is a significant factor contributing to an increase in the number of people afflicted by snoring disorders in the area. Obesity is a serious problem, particularly in the United States, and is mostly brought on by an increase in the consumption of processed foods and a rising trend toward a sedentary lifestyle. Additionally, the existence of market participants in this region and the accessibility of items on retail and e-commerce websites will increase market penetration and product reach. Furthermore, the advanced anti-snoring device's increased availability, more knowledge of the effects of airway obstruction, and increased disposable income to treat conditions like snoring, among other factors, are anticipated to boost the market in the years to come.